NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.

Clever Culture’s APAS is now on trial with Novo Nordisk, and if it delivers, this one machine could unlock a global pharma ...

Connecticut passed a new law last week in an effort to lower its spending on weight-loss drugs for its state insurance ...

Hims & Hers bounced back by 8.64 percent on Monday to close at $52.03 following announcements that it remains open to working ...

Hims & Hers Health Inc. board members and executives failed to tell shareholders that its Novo Nordisk A/S Wegovy ...

Cheaper versions of medications to treat obesity, like Ozempic and Wegovy, could be on the market in Canada as soon as ...

Adventurous speculators interested in a quick-strike opportunity may want to set their sights on Novo Nordisk (NYSE: NVO ).

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...

Proposals by Robert F. Kennedy Jr. and Bernie Sanders range from more disclosures in commercials to an outright ban.

If you have $1,000 to invest right now, you may be wondering where to get started. You could buy stocks that are flying high ...

EUROPEAN shares ended lower on Tuesday, dragged down by heavyweight financial and healthcare stocks as investors awaited news ...

Innovent Biologics, the first Chinese firm to gain approval for a GLP-1 weight loss and diabetes drug, has partnered with JD ...